Recently published Neuromyelitis Optica Spectrum Disorder Market Insights report includes a comprehensive understanding of current treatment practices, neuromyelitis optica spectrum disorder emerging ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.

Autoimmune diseases cannot currently be cured, only treated, and this is also true for neuromyelitis optica spectrum disorder, which affects the central nervous system. A Kobe University study of how ...

Please provide your email address to receive an email when new articles are posted on . The therapy demonstrated an acceptable safety profile and reduced the risk of NMOSD attacks with two infusions ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

– First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks – – First ...

In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system.

Twenty NMOSD patients representing the general patient population were convened to discuss their employment experiences. Participants reported employment issues due to high disease burdens, a lack of ...

The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026-2036), mainly attributed to the increasing prevalence of ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April ...